Clinical evidence for different narcotic receptors and relevance for the clinician.

[1]  W R Martin,et al.  Pharmacology of opioids. , 1983, Pharmacological reviews.

[2]  D. Jasinski,et al.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. , 1978, Archives of general psychiatry.

[3]  W. Martin,et al.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[4]  D. Jasinski,et al.  Evaluation of nalbuphine for abuse potential , 1972, Clinical pharmacology and therapeutics.

[5]  R. Hoeldtke,et al.  Studies of the dependence‐producing properties of GPA‐1657, profadol, and propiram in man , 1971, Clinical pharmacology and therapeutics.

[6]  R. Hoeldtke,et al.  Effects of short‐ and long‐term administration of pentazocine in man , 1970, Clinical pharmacology and therapeutics.

[7]  W. Forrest,et al.  Respiratory and subjective effects of d‐ and I‐pentazocine , 1968, Clinical pharmacology and therapeutics.

[8]  W. Martin,et al.  Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3). , 1965, The Journal of pharmacology and experimental therapeutics.

[9]  J. Henningfield,et al.  Progress report of the NIDA Addiction Research Center, Baltimore, Maryland, 1982. , 1983, NIDA research monograph.

[10]  Orwin Jm.  The effect of doxapram on buprenorphine induced respiratory depression. , 1977 .

[11]  Haertzen Ca.  Subjective effects of narcotic antagonists. , 1973 .

[12]  N. B. Eddy.  The National Research Council involvement in the opiate problem, 1928-1971 , 1973 .